Understand the current status, when a generic version will be available, FDA-approved alternatives, and cost-saving tips
5a and c are representative of four different microscopy sessions
Medically reviewed by Lauren Okafor | MD , The Frank H Netter MD School of Medicine, Loyola University Medical Center on April 8th, 2026
The FDA subsequently announced a timeline for when most compounded versions may no longer be made
By activating both GIP and GLP-1 receptors, Mounjaro enhances insulin secretion in response to meals, suppresses glucagon release, slows gastric emptying, and reduces appetitemechanisms that collectively improve glycaemic control and promote weight loss
If chronic pancreatitis is stable with imaging confirmation and normal enzyme levels, semaglutide may be an option